Smith FO, Loh ML. Myelodysplastic and myeloproliferative syndrome in children. In: Hoffman R, Benz EJ, Shattil SJ, Furie B, Silberstein LE, McGlave P, et al., editors. Hematology: basic principles and practice. 5th ed. Philadelphia (PA): Churchill Livingstone; 2008.
Juvenile myelomonocytic leukemia is a type of a myelodysplastic syndrome. The only treatment that has resulted in cures for JMML is a bone marrow transplant, with about a 50% survival rate. The risk of relapsing after transplant is high, and has been recorded as high as 50%. However, there is no other treatment that has a comparative cure rate and allogeneic transpalntation is supported by a number of studies as well as revieews and is recommended by PDQ.
Taussig DC, Davies AJ, Cavenagh JD, Oakervee H, Syndercombe-Court D, Kelsey S, et al. Durable remissions of myelodysplastic syndrome and acute myeloid leukemia after reduced-intensity allografting. J Clin Oncol. 2003 Aug 15;21(16):3060-5.
Yoshimi A, Mohamed M, Bierings M, Urban C, Korthorf E, Zecca M, et al. Second allogeneic hematopoietic stem cell transplantation (HSCT) results in outcome similar to that of first HSCT for patients with juvenile myelomonocytic leukemia. Leukemia. 2007 Mar;21(3):556-60. Epub 2007 Feb 1.
Yusuf U, Frangoul HA, Gooley TA, Wooolfrey AE, Carpenter PA, Andrews RG, et al. Allogeneic bone marrow transplantation in children with myelodysplastic syndrome or juvenile myelomonocytic leukemia: the Seattle experience. Bone Marroe Transplant. 2004Apr;33(8)805-14.